Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2018

View Archived Issues

Next-generation polymyxins could bring immunotherapy to antibiotics

New hSTING agonists presented as cancer immunotherapy agents

pAAV.CMV.miR204 shows protective effect on photoreceptors in models of inherited retinal disease

Researchers unveil NAXD gene as causative of a neurodegenerative disorder

Compound CAR T cells targeting CLL1 and CD33 in refractory acute myeloid leukemia: phase I results

First human data presented for prostate cancer imaging agent [68Ga]PSMA-093

Embryonic stem cells make helpful heart muscles

New mutations in SLC25A24 gene found to cause Fontaine syndrome

Pivotal phase III trial of Pixuvri in B-cell NHL does not meet primary endpoint

Promising interim data presented from phase I study of oral carbapenem SPR-994

Assembly Biosciences initiates phase IIa studies of ABI-H0731 for HBV

Codexis begins dosing in first-in-human study of CDX-6114 for PKU

Phase III trial of luspatercept in transfusion-dependent beta-thalassemia meets primary endpoint

Intrapulmonary penetration of ETX-2514SUL supports development for respiratory infections

MediciNova announces subgroup analyses from trial of MN-166 in ALS

Catabasis announces plans for phase III trial of edasalonexent in DMD

Bellus Health initiates phase I study of BLU-5937 for the treatment of chronic cough

Matinas collaborates with NINDS to develop HIV therapy based on LNC platform

CPL-207-280CA demonstrates improved glycemic control and safety in vivo

Amgen discovers new beta-secretase inhibitors

KCNC1/KCNC2 channel modulators presented by Autifony Therapeutics

Pfizer divulges glucagon-like peptide 1 receptor agonists

Cassiopea reports phase III topline results for topical antiandrogen Winlevi for acne

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...